www.rtog.org 1

WELCOMEWELCOME

To The Semi-AnnualTo The Semi-Annual

RTOGRTOG

RA OrientationRA Orientation

Tampa Florida Tampa Florida

February 1February 1stst , 2007 , 2007

www.rtog.org 2

Established in 1968

Over 250 facilities participate in RTOG trials

United States United States

CanadaCanada

FranceFrance

IsraelIsrael

AustraliaAustralia

NCI Funding and Corporate Support

RTOG BACKGROUNDRTOG BACKGROUND

www.rtog.org 3

Opened 300 ProtocolsOpened 300 Protocols

Accrued 60,000 patients to cooperative Accrued 60,000 patients to cooperative group studiesgroup studies

Published more than 700 papersPublished more than 700 papers

Maintains a roster of 40 active studies Maintains a roster of 40 active studies devoted to the group’s primary disease sitesdevoted to the group’s primary disease sites

www.rtog.org 4

RTOG PRIMARY DISEASE SITESRTOG PRIMARY DISEASE SITES

CNSCNS

Head & NeckHead & Neck

LungLung

BreastBreast

www.rtog.org 5

RTOG PRIMARY DISEASE SITESRTOG PRIMARY DISEASE SITES

GYNGYN

GenitourinaryGenitourinaryBladderBladderProstateProstate

GastrointestinalGastrointestinalEsophagusEsophagusRectumRectumAnal CanalAnal CanalStomachStomach

www.rtog.org 6

MISSIONMISSION

Improve survival outcome and quality of life of adults withImprove survival outcome and quality of life of adults with cancercancer

Evaluate new forms of radiotherapy delivery.Evaluate new forms of radiotherapy delivery.[brachytherapy, 3-dimensional conformal radiotherapy,[brachytherapy, 3-dimensional conformal radiotherapy,

intensity modulated radiotherapy (IMRT ]intensity modulated radiotherapy (IMRT ]

Test new systemic therapies in conjunction with RTTest new systemic therapies in conjunction with RT[chemotherapy, hormonal treatment, biologic agents and[chemotherapy, hormonal treatment, biologic agents andnew classes of cytostatic, cytotoxic and targeted therapies]new classes of cytostatic, cytotoxic and targeted therapies]

Employ translational research strategies to identify patientEmploy translational research strategies to identify patient subgroups at risk for failure with existing treatments andsubgroups at risk for failure with existing treatments and identify new approaches for these patientsidentify new approaches for these patients

www.rtog.org 7

RTOG STAFFRTOG STAFF

Over 60 RTOG staff membersOver 60 RTOG staff members

AdministrativeAdministrative

Research AssociatesResearch Associates

StatisticiansStatisticians

Quality AssuranceQuality Assurance

Protocol DevelopmentProtocol Development

www.rtog.org 8

RECENT RECENT ACCOMPLISHMENTSACCOMPLISHMENTS

www.rtog.org 9

CERVIX CANCERCERVIX CANCER

• RTOG demonstrated RTOG demonstrated that combining that combining chemotherapy with chemotherapy with pelvic radiation pelvic radiation improves the 5 year improves the 5 year survival rate for women survival rate for women with locally advanced with locally advanced cervix cancer fromcervix cancer from

58% to 73%.58% to 73%.

www.rtog.org 10

LUNG CANCERLUNG CANCER

• RTOG FOUND THAT RTOG FOUND THAT HEALTHIER PATIENTS WITH HEALTHIER PATIENTS WITH INOPERABLE NON-SMALL-INOPERABLE NON-SMALL-CELL LUNG CANCER HAD CELL LUNG CANCER HAD BETTER RESULTS IF THEY BETTER RESULTS IF THEY RECEIVED RECEIVED CHEMOTHERAPY CHEMOTHERAPY DURINGDURING RADIOTHERAPY RATHER RADIOTHERAPY RATHER THAN PRIOR TO THAN PRIOR TO RADIOTHERAPY.RADIOTHERAPY.

www.rtog.org 11

HEAD AND NECKHEAD AND NECK

• RTOG demonstrated the RTOG demonstrated the superiority of concomitant superiority of concomitant boost radiotherapy and boost radiotherapy and hyperfractionated radiotherapy hyperfractionated radiotherapy for locally advanced squamous-for locally advanced squamous-cell carcinoma.cell carcinoma.

• RTOG demonstrated that RTOG demonstrated that patients who received patients who received chemotherapy together with chemotherapy together with their radiotherapy after surgery their radiotherapy after surgery were far less likely to have a were far less likely to have a recurrence of their cancer.recurrence of their cancer.

www.rtog.org 12

BRAINBRAIN

• RTOG improved survival RTOG improved survival more thanmore than

33%33%

for patients with a single for patients with a single brain metastasis by using brain metastasis by using whole brain radiotherapy whole brain radiotherapy followed by stereotactic followed by stereotactic radiosurgery boost instead radiosurgery boost instead of whole brain treatment of whole brain treatment alonealone..

www.rtog.org 13

CNS LYMPHOMACNS LYMPHOMA

• RTOG improved the median RTOG improved the median survival for patients with survival for patients with non-AIDS-related primary non-AIDS-related primary

CNS lymphoma fromCNS lymphoma from

11.6 11.6 monthsmonths to to

30.4 30.4 monthsmonths

by giving high dose by giving high dose chemotherapy for 10 weeks chemotherapy for 10 weeks prior to RT.prior to RT.

www.rtog.org 14

THANK YOU !THANK YOU !